NCT03651219 is a Phase 3 clinical trial of Apatinib in Small Cell Lung Cancer, sponsored by Beijing Chest Hospital.

Who is sponsoring NCT03651219?

NCT03651219 is sponsored by Beijing Chest Hospital.

What drugs are being tested in NCT03651219?

Interventions in NCT03651219: Apatinib, Irinotecan.

What condition does NCT03651219 study?

NCT03651219 studies Small Cell Lung Cancer.

Is NCT03651219 still recruiting?

NCT03651219 is currently status unknown. Last updated 29 August 2018.

Last reviewed 2018-08-29 · How we verify

NCT03651219

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

Status unknown Phase 3 Last updated 29 August 2018

What this trial tests

Phase 3 trial testing Apatinib in Small Cell Lung Cancer in 90 participants. Status unknown.

Timeline

8 September 2018

Primary endpoint
8 August 2019

8 August 2020

Quick facts

Lead sponsor	Beijing Chest Hospital
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	8 September 2018
Primary completion	8 August 2019
Estimated completion	8 August 2020

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →
Irinotecan (irinotecan) — full drug profile →

Conditions studied

Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →

Sponsor

Beijing Chest Hospital

Who can join

Adults 18 to 70, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the safety and efficacy of apatinib mesylate tablets and chemotherapy drug Irinotecan in treatment of recurrent SCLC stage IIIB\&IV patients. It is a randomized controlled clinical trial.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Actionable Driver Events in Small Cell Lung Cancer.
Gutiérrez M, Zamora I, Freeman MR, Encío IJ, et al · · 2023 · cited 3× · PMID 38203275 · DOI 10.3390/ijms25010105
Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future.
Wakuda K. · · 2020 · cited 1× · PMID 32420056 · DOI 10.21037/tlcr.2020.03.10

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other recruiting trials for Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Other Beijing Chest Hospital trials

Trials by the same sponsor.

NCT07372781 — Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease · Phase 2 · enrolling by invitation
NCT07268664 — Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort · Phase 3 · not yet recruiting
NCT06809413 — Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease · Phase 2 · enrolling by invitation
NCT06764368 — Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors · Phase 2 · not yet recruiting
NCT06811025 — Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis · Phase 1, PHASE2 · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03651219 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Chest Hospital
Last refreshed: 29 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03651219.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing